Philadelphia, PANCT06055361Now EnrollingIRB Ready

Atopic Dermatitis Clinical Trial in Philadelphia, PA

Access cutting-edge atopic dermatitis treatment through this phase 1 clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by Brexogen Inc.

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access atopic dermatitis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related atopic dermatitis treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this atopic dermatitis clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Atopic Dermatitis Study in Philadelphia

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)

Sponsor: Brexogen Inc.

Who Can Participate

Inclusion Criteria

Patients (males or females) aged 18 years or older.
Patients have documented history of moderate to severe AD, that has been present for at least 1 year
History of inadequate response to a stable regimen of TCSs or TCIs as treatment for AD
Patients must agree to apply stable doses of additive-free, basic bland emollient lotions twice daily for at least 7 days before the Baseline Visit.
Willingness and ability to comply with clinic visits and study-related procedures.
Patients should be able to read, understand, and be willing to sign the ICF

Exclusion Criteria

Presence of any of the following laboratory abnormalities
Hemoglobin \< 11 g/dL
WBC \< 3.5 × 103/μL
Platelet count \< 125 × 103/μL
Neutrophils \< 1.75 × 103/μL
AST/ALT \> 1.5 × ULN
Total bilirubin \> ULN
Creatinine \> ULN
Creatine phosphokinase \> ULN
Positive test for hepatitis B surface antigen, and/or hepatitis C antibody
Active dermatologic conditions that may confound the diagnosis of AD
Prior exposure to any investigational systemic treatment or is currently enrolled in another clinical study
Significant concomitant illness or history of significant illness such as cardiac, renal, neurological, endocrinological, metabolic or lymphatic disease, or any other illness or condition that would adversely affect the patient's participation in this study
Treatment with TCS, and/or TCI, within 1 week prior to the Baseline Visit.
Known history of human immunodeficiency virus (HIV) infection
Pregnant or breastfeeding women

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT06055361) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Atopic Dermatitis Treatment Options in Philadelphia, PA

If you're searching for atopic dermatitis treatment options in Philadelphia, PA, this clinical trial (NCT06055361) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced atopic dermatitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all atopic dermatitis clinical trials near you to find additional studies recruiting in your area.

More Atopic Dermatitis Trials in Philadelphia, PA

See all atopic dermatitis clinical trials recruiting in Philadelphia — not just this study.

Browse Atopic Dermatitis Trials in Philadelphia →

Browse More Trials by Condition

Atopic Dermatitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA